Drug-Related Problems in Patients with Benign Prostatic Hyperplasia: A Cross Sectional Retrospective Study

Hasniza Zaman Huri,Chong Hui Xin,Che Zuraini Sulaiman,Anthony W I Lo

doi:10.1371/journal.pone.0086215

Hasniza Zaman Huri, Chong Hui Xin + Show 2 more

Open Access

https://doi.org/10.1371/journal.pone.0086215

Copy DOI

Journal: PLoS ONE	Publication Date: Jan 27, 2014
Citations: 61	License type: CC BY 4.0

Affiliation: University Malaya Medical Centre, University of Malaya

Abstract

Benign Prostatic Hyperplasia (BPH) patients are at risk of acquiring drug-related problems (DRPs), as it is present in the majority of aging men. To date, DRPs among BPH patients have not been well studied. We conducted this retrospective study in a tertiary hospital in Malaysia from January 2009 to June 2012 with the aim of identifying the factors associated with DRPs among BPH patients. The Pharmaceutical Care Network Europe Classification Version (PCNE) 5.01 was used as a tool to classify DRPs. We enrolled 203 patients from 259 hospital admissions. A total of 390 DRPs were found and there was an average of 1.5±1.3 problems per hospitalization. 76.1% of hospital admissions included at least one DRP. The most common DRP categories encountered were drug choice problems (45.9%), drug interactions (24.9%), and dosing problems (13.3%). Factors such as advanced age (p = 0.005), a hospital stay of more than 6 days (p = 0.001), polydrug treatments (p<0.001), multiple comorbidities (p<0.001), and comorbid cardiovascular disease (p = 0.011), diabetes mellitus(p = 0.001), hypertension (p<0.001) and renal impairment (p = 0.011) were significantly associated with the occurrence of DRPs. These data indicated that the prevalence of DRPs is high among BPH patients. The identification of different subtypes of DRPs and the factors associated with DRPs may facilitate risk reduction for BPH patients.

Highlights

Benign Prostatic Hyperplasia (BPH) is a common disorder, which refers to the proliferation of stromal and epithelial cells within the prostate [1]
BPH is usually associated with a series of lower urinary tract symptoms (LUTS), including nocturia, increased urinary hesitancy, frequency and urgency, as well as a weak dribbling stream of urine and increased post-voiding residual volumes
To identify factors associated with the drug-related problems in patients with benign prostatic hyperplasia

Summary

Introduction

Benign Prostatic Hyperplasia (BPH) is a common disorder, which refers to the proliferation of stromal and epithelial cells within the prostate [1]. BPH is usually associated with a series of lower urinary tract symptoms (LUTS), including nocturia, increased urinary hesitancy, frequency and urgency, as well as a weak dribbling stream of urine and increased post-voiding residual volumes. The prevalence of BPH is progressive and increases linearly with age [1].The American Urological Association has demonstrated that symptomatic BPH affects 50% of men at the sixth decade of life and the prevalence increases to up to 90% of men aged above 85 years [2]. The Ministry of Health of Malaysia (MOH) has reported that the prevalence of BPH in men aged above 60 years is about 50% and rises to up to 82% of men aged 71 to 80 years [3]. Transurethral Resection of the Prostate (TURP) was the most common treatment for BPH during the last decade. A1-adrenergic blockers and 5a-reductase inhibitors have been accepted as standard medical therapies for BPH since the 1990s, as they are approved to improve urinary functions in men with BPH [5]

Objectives

Methods

Results

Discussion

Conclusion